Results 51 to 60 of about 13,441 (261)
Addiction, EarlyView.Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden +10 more
wiley +1 more source
Ayahuasca and Globalization [PDF]
, 2011 The essay explores the globalization of ayahuasca, a plant medicine endemic to the Upper Amazon. Originally distributed among only Indigenous Amazonian people, today it is distributed throughout the globe. Contemporary consumers of ayahuasca construct it
Hudson, Jesse
core +2 more sources
Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada
Addiction, EarlyView.Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran +9 more
wiley +1 more source
, 2017 In this chapter, we introduce the notion of “moral neuroenhancement,” offering a novel definition as well as spelling out three conditions under which we expect that such neuroenhancement would be most likely to be permissible (or ...
Douglas, Thomas +2 more
core
Hallucinogen Rating Scale (HRS) - A Brazilian version: translation and cross-cultural adaptation [PDF]
, 2011 BACKGROUND: There is a growing scientific interest in the effects of hallucinogens in general and the religious use of psychoactive brew ayahuasca in Brazil in particular.
Barbosa, Paulo César Ribeiro +3 more
core +3 more sources
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish
Frontiers in Behavioral Neuroscience, 2017 The combined infusion of Banisteriopsis caapi stem and Psychotria viridis leaves, known as ayahuasca, has been used for centuries by indigenous tribes.
Robson Savoldi +7 more
doaj +1 more source
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, EarlyView.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Chronic intermittent exposure to ayahuasca during aging does not affect memory in mice
Brazilian Journal of Medical and Biological ResearchThe Quechua term ayahuasca refers to a beverage obtained from decoctions of the liana Banisteriopsis caapi with leaves of Psychotria viridis. The ritualistic use of ayahuasca is becoming a global phenomenon, with some individuals using this beverage ...
N.F. Correa-Netto +7 more
doaj +1 more source